AbbVie Inc. Stock
€226.20
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade
Key Points
- Interested in AbbVie Inc.? Here are five stocks we like better.
- Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
AbbVie's (NYSE: ABBV) share price has been under pressure due to rising costs and concerns that its post-Humira days won’t be as robust. However, the stock price decline put the market in a
3 Companies Aggressively Raising Dividends While Others Play Defense
Dividend growth stocks may be worth a closer look heading toward the midpoint of 2026, given extreme geopolitical turbulence and concerns about inflation or a recession that are sending skittish
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal
When the price of a high-quality stock such as AbbVie (NYSE: ABBV) declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to
AbbVie Call Options Spike 2,599%: Tracking the Big Bet
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
AbbVie's (NYSE: ABBV) financial results have been strong recently, largely thanks to its key growth drivers, Skyrizi and Rinvoq. However, both of these immunosuppressants will lose patent
3 No-Brainer Dividend Stocks to Buy Right Now
With the S&P 500 looking historically expensive at 31 times earnings, it's a good time to buy a few defensive dividend stocks to hedge against a market crash. These stocks might also swoon during a
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
When a stock hits a new 52-week high, it can be a sign that things are going well for the business and that investors are recognizing some encouraging value. However, it also means that the stock
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
Investors seeking reliable dividends often look to the healthcare sector, but choosing between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) requires a close look at their post-pandemic growth
Is AbbVie a Buy After Its Purchase of Apogee?
Pharmaceutical giant AbbVie (NYSE: ABBV) made a bold move this past Monday when it announced its planned $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE).
The deal would bring a
Why AbbVie Stock Jumped Today
Shares of AbbVie (NYSE: ABBV) climbed on Monday after the pharmaceutical giant struck a deal to acquire clinical-stage biotech Apogee Therapeutics (NASDAQ: APGE) for $10.9 billion.
Image source
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
AbbVie (NYSE:ABBV) was one of the livelier stocks in Monday’s trading session. It was also one of the better-performing equities, gaining more than 6% that day. Much of this was due to a splashy new
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
Apogee Therapeutics (NASDAQ:APGE), a clinical-stage biologics company for inflammatory and immunology disorders, closed at $132.55, up 46.66%. AbbVie’s proposed $135.11-per-share cash acquisition
3 Excellent Dividend Stocks to Buy on the Dip
Many investors are chasing life-changing gains by buying shares in top artificial intelligence companies. That makes sense. The industry could offer (and already has offered) multiple transformative
Health Care ETFs: XLV Delivers Low Fees and Solid Returns
Choosing between the State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) and the iShares U.S. Healthcare ETF (NYSEMKT:IYH) often comes down to a preference for lower fees versus broader
3 High-Yield Dividend Stocks to Buy Hand Over Fist in June
Rate cuts appear to be off the table for now due to surging inflation and a relatively strong jobs market. The current dynamics could drive increased market volatility, but they could also make
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.
That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
When it comes to major dividend growth stocks, many come to mind, particularly widely held consumer staples stocks. However, because of their popularity, many have arguably become stretched in terms
The Best Stocks to Invest $500 in Right Now
Some investors are avoiding the healthcare sector right now due to its lagging the market in recent years and its somewhat uncertain outlook. However, this bearish sentiment could mean there are
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
Despite its shares being in the red year to date, AbbVie's (NYSE: ABBV) financial results have been strong. The company's first-quarter update, released on April 29, came in ahead of expectations on
3 Dividend Stocks to Buy and Hold Forever
The healthcare sector has faced challenges in recent years due to regulatory pressures and a somewhat uncertain outlook. However, thanks in part to its defensive nature and the fact that excellent
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both giants face patent cliffs but pursue very different
What's the Better Dividend Stock Today: AbbVie or Pfizer?
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two top healthcare stocks, and they're investments that can generate a ton of dividend income for your portfolio.
AbbVie, which yields 3.2%, has been a
The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
When investors are in a risk-on mood, they often gravitate to growth-oriented technology stocks. When investors are in a risk-off mood, however, they often rotate out of tech and into other areas